Manufacturing
Scalable production and proprietary device development for plastic surgery and orthopedic demand.
The problem
Meet Carlos. He wanted to look younger, without a facelift.
A busy baby boomer, Carlos worried about visible scars, a “pulled” look, anesthesia and a long recovery, and med spa treatments couldn’t give him lasting results. He is one of millions: a multi-billion dollar gap affecting up to 90% of men and women, with no national solution.
Before
24 hours later“Pretty remarkable. I really honestly didn’t think you would be able to take off all the saggy skin that was under my neck.”
Carlos · 24 hours after his procedureInvestment thesis*
Look ten years younger, in one hour.
ReLiftMD™ has developed minimally invasive ReLift® procedures using proprietary materials, performed in about an hour under local anesthesia. The founding surgeon has proven high patient satisfaction, high demand and highly favorable economics.
Board-certified plastic surgeons nationwide are joining, and have invested in the company. Accredited investors are now invited to accelerate the expansion, with prioritized distributions, a unique liquidity feature and equity in the national roll-up.
Track record · founding surgeon*
Proven in one clinic. Built to repeat.
2,200+Patients treated
$32MMReLift® procedure revenue
$5,000Annual recurring revenue per patient
$20K+Lifetime value per patient
Operating profit has grown every year, with one surgeon.
2025: $1.75 million in sales and $694,655 in operating profit from a single clinic.
202320242025
Demand · both sides of the table
Patients want it. Surgeons want in.
The roll-up rests on two kinds of demand: patients who choose the ReLift® procedure and tell others about it, and board-certified plastic surgeons who want to offer it in their own markets. Hear both, in their own words.
Patient demand
“I would tell anybody around me, it is worth the drive.”
2,200+Patients treated
OneFounding clinic
Patient voices · 1:59. Patient stories are shared with written authorization and reflect individual experiences. Individual results vary. Patients were not compensated for their testimonials.
Surgeon demand
“Here’s one that really makes sense and is a real thing.”
06 of 15Founder’s Circle seats committed
Founder’s Circle highlights · 1:24. Excerpts from a recorded Founder’s Circle meeting, August 2026, shared with the participants’ permission. Views are those of the individual surgeons.
The market
A multi-billion dollar industry with no national brand.
Elective medical services are a $627 billion market, nearly half of it aesthetic. Laser vision and body contouring each built a national brand. Facial rejuvenation, with the highest margins of the three, has not.
| Category | US · Global | CAGR | National brand | Centers | Revenue | Margin | Margin influences |
|---|---|---|---|---|---|---|---|
| Laser vision correction | $3.8B · $9.1B | 8.1% | LasikMD | 600 | $148MM | 30% | High capex, recurring costs, competition |
| Body contouring | $4.0B · $5.7B | 6.8% | Sono Bello | 100 | $500MM | 35% | High capex, no moat, limited offerings |
| Facial rejuvenation | $12B · $54B | 10% | None yet | — | — | 65% | Low capex, protected moat, recurring revenue |
Medical aesthetics: $91B to $213B in ten years.
The global market was $83 billion in 2023 and $91 billion in 2024, and is forecast to reach $213 billion by 2034, growing about 9.7% a year.
Reported · 2023, 2024Interim yearsForecast · 2034
Global market, US dollars. Straits Research (2024). 2025–2033 are interpolated at a constant annual growth rate between the 2024 base year and the 2034 forecast, for illustration.
Sources: Global Growth Insights, “Elective Healthcare Services” (2025); Business Research Insights; Market Research Future (2025); Tracxn; Straits Research (2024). Third-party estimates.
The business model
Three engines, one balance sheet.
ReLiftMD™ manufactures ReLift® devices, drives patient traffic to partner surgeons, and exits through a national roll-up. Ancillary revenue comes from B2B and B2C product sales.
MSO
A management services organization providing turnkey operations, marketing and compliance to partner surgeons.
Roll-up
Strategic acquisition and integration of high-performing elective medical clinics nationwide.
Why the model scales
Low capex, low opex
Each ReLift® Center uses the partner’s existing space, staff and OR capacity.
Cash flow funds scale
Partner surgeons invest $100K, and each Center brings about $1MM in pre-paid sales revenue a year.
Disciplined leverage
A low-utilization asset-based credit line creates a liquidity flywheel for the roll-up and equity appreciation.
The five-year growth plan*
Two phases to 250 practices.
A national network of partner surgeons.
250 certified plastic surgeons, each performing four or more ReLift® procedures a month, with the ReLift® Business Network and patient membership programs.
Certified plastic surgeons250
Added annual profit per practice$250K–$500K
Consolidation into one national brand.
A non-dilutive roll-up, with acquisitions powered by a revolving credit facility, unlocking institutional multiples by consolidating fragmented clinic earnings.
Plastic surgery clinics250
Enterprise EBITDA$300MM
Terminal valuation$3B
Network clinics, year by year.
From ten clinics in year one to 250 by year five.
10Year 1
50Year 2
100Year 3
150Year 4
250Year 5
The offering*
$50 million, through a dedicated Reg D 506(c) SPV.
Capital funds the national expansion of 250 ReLift® Centers through the MSO and production of proprietary materials through Fabrication. Accredited investors may participate with $100,000.
25%Target IRR over 3–5 years from distributions, with a full return of capital.
5x+Targeted ROI from Fabrication, positioned for an acquisition with a minimum floor of 5x.
8x+Targeted ROI with an IPO of the MSO and roll-up.
How the returns are structured
Paid along the way, then rewarded at the exit.
Step 1 · Invest
From $100,000
Accredited investors join through the dedicated SPV.
Step 2 · Distributions
Cash first
100% of net profits go to investors first, targeting a 25% IRR over 3–5 years and a full return of capital.
Step 3 · Equity
Units at full value
Equity units carry a liquidation value equal to the initial investment, with redeemable-share liquidity.
Step 4 · Exit
Two liquidity events
An acquisition of Fabrication (5x floor) and a public exit of the MSO (10x+).
What the targets mean on $100,000.
Simple arithmetic of the targeted multiples applied to the minimum investment. An illustration of the targets only, not a projection or a promise.
Invested5x8x10x20x
Investor protections
Investors first
A cash-first structure distributes 100% of net profits to investors.
Participating preferred
Preferential return of capital, plus a share of any upside.
Liquidity
Redeemable shares allow an exit with 100% return of capital, subject to liquidity.
Non-dilutable equity
Investors cannot be diluted by future small rounds.
Pro rata rights
Right of first refusal on future capital raises.
Information rights
Confidential operating and financial updates.
Tag-along rights
Sell alongside major shareholders.
No capital calls
No additional capital is required after investment.
Questions investors ask
Before the live Q&A.
What is the investment opportunity?
ReLiftMD Ventures, LLC, a Reg D 506(c) dedicated SPV, is raising $50MM. Phase I funds the national expansion of 250 ReLift® Centers and production of proprietary ReLift® materials. Phase II rolls up the clinics to unlock institutional multiples.
Why ReLiftMD™ instead of other opportunities?
A dual revenue structure, device sales and MSO fees; procedures that require current ReLift® devices; a category growing above 10% a year; Centers expected to generate over $1MM annually each; and a model proven with over $32MM in revenue and 2,200 patients.
How are returns paid?
Investors are prioritized to receive distributions from operating cash flow, targeting a 25% IRR over 3–5 years with a full return of capital. Equity value is targeted through an acquisition of the manufacturing division and an IPO of the MSO.
What is the minimum investment?
Accredited investors may participate with $100,000.
Live every Monday · 8:00 PM ET · Zoom
Ask the founder directly.
Each Monday, Dr. Adam Summers and COO Curt Clinkinbeard walk through the track record, the five-year build and the offering, then take your questions live.
Mondays · 8:00 PM ET · Zoom